Akero Therapeutics — Investor Presentation (January 2020)
19 slides from Akero Therapeutics's investor presentation, Jan 13, 2020
Slide 1: Restoring Metabolic Balance. Transforming Lives.
RESTORING METABOLIC BALANCE. TRANSFORMING LIVES. Developing medicines to reverse the course of serious metabolic diseases. CORPORATE PRESENTATION - CONFIDENTIAL
Slide 2: Safe Harbor
SAFE HARBOR This presentation has been prepared by Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securitie
Slide 3: Akero: Building Value on a Strong Foundation
AKERO BUILDING VALUE ON A STRONG FOUNDATION • AKR-001, Fc-FGF21 fusion protein, licensed from Amgen 3-4 day half-life for QW dosing Robust effects on lipoproteins and markers of insulin sensitivity in 83 T2D patients in two Phase 1 trials Well tolerated Currently in Phase 2a • FGF analogs reduce liv
Slide 4: NASH: A Serious and Debilitating Multi-System Disease
NASH A SERIOUS AND DEBILITATING MULTI-SYSTEM DISEASE NASH epidemic fueled by rise in obesity and diabetes No treatments currently available A GROWING HEALTH EPIDEMIC The number of NASH patients with advanced-stage fibrosis and cirrhosis is predicted to grow to 8 million in the US by 2030, an increas
Slide 5: FGF21 Acts on Two Major Sources of Liver Fat
FGF21 ACTS ON TWO MAJOR SOURCES OF LIVER FAT WITH POTENTIAL FOR OPTIMAL REDUCTION Sources of Fat Flowing into and Through Liver for NASH Patients Acting on both hepatic and peripheral sources of liver fat is key to optimizing liver fat reduction Dietary Fat (10-20%) Adipose Tissue: Lipolysis (40-50%
Slide 6: FGF21 Protects Hepatocytes and Mitigates Inflammation & Fibrosis
FGF21 PROTECTS HEPATOCYTES AND MITIGATES INFLAMMATION & FIBROSIS Inhibition of Kupffer cells reduces inflammation and cell death Reduction of cell death reduces inflammation Reduction in hepatocyte stress pathways reduces cell death Inhibition of Hepatic Stellate Cell differentiation into myofibrobl
Slide 7: AKR-001 Engineering Potentially Optimal for NASH Efficacy
AKR-001 ENGINEERING POTENTIALLY OPTIMAL FOR NASH EFFICACY, WITH CONVENIENT ONCE-WEEKLY DOSING Key attributes Amgen-designed Fc-FGF21, Point mutations Increases half-life from < 2 hours to 3-4 days High affinity for β-Klotho Better translation to human pharmacology Balanced potency at FGFR1c, 2c, 3c
Slide 8: AKR-001 Restored Metabolic Balance in Phase 1
AKR-001 RESTORED METABOLIC BALANCE AND IMPROVED MARKERS OF CARDIOVASCULAR RISK IN PHASE 1 Two Phase 1 clinical trials of AKR-001 studying 83 patients with type 2 diabetes showed Improved Lipoproteins Improved Insulin Sensitivity Weight Neutrality Favorable Tolerability And support AKR-001’s potentia
Slide 9: AKR-001 Improved Lipoprotein Profile
AKR-001 IMPROVED LIPOPROTEIN PROFILE AKR-001’s significant improvements in lipoproteins and reduction in adipose lipolysis are consistent with effective agonism of FGFR2c and 3c in the liver and FGFR1c in adipose tissue Triglyceridesa LDL-Ca Non-HDL-Ca HDL-Ca ApoBb 20% 10% 0% -10% -20% -30% -40% -50
Slide 10: AKR-001 Improved Lipoproteins Rapidly and Durably
AKR-001 IMPROVED LIPOPROTEINS RAPIDLY AND DURABLY AKR-001 70 mg QW effects on lipoproteins in Phase 1b clinical trial 6,800 *** *** *** 50% *** *** 4,300 30% * ** 4th Dose 1,800 10% -700 -10% * -3,200 -30% * ** *** -5,700 -50% * *** ** ** * = p<0.05 ** = p<0.01 *** ****** *** *** *** *** *** 14 ***
Slide 11: AKR-001 Improved Insulin Sensitivity
AKR-001 IMPROVED INSULIN SENSITIVITY AKR-001’s significant improvement in insulin sensitivity is consistent with effective FGFR1c agonism Insulina Glucosea C-Peptidea HOMA-IRa Adiponectinb 15% 20% 10% 0% 120% 10% 0% 10% 100% -10% 107% 5% -10% 0% 80% ** -20% 0% -20% -10% 60% -5% -30% -30% -20% -29% 4
Slide 12: Historical Data Validate Potential for Balanced FGFR Agonism
HISTORICAL DATA VALIDATE POTENTIAL FOR BALANCED FGFR AGONISM TO Relative Fat Reduction (MRI-PDFF) of FGFs REDUCE LIVER FAT pegbelfermin PEG-FGF21 (20mg, QW) pegbelfermin PEG-FGF21 (10mg, QD) MRK-3655 FGFR1c/B-Klotho (240mg, 1 dose) aldafermin FGF19 (3mg, QD) aldafermin FGF19 (1mg, QD 24wk) 0% Balanc
Slide 13: Positive Data for FGFR Agonist in Liver Histology
POSITIVE DATA FOR FGFR AGONIST IN LIVER HISTOLOGY UNDERSCORES POTENTIAL FOR AKR-001 AKR-001 is a balanced agonist of FGFR1c, 2c and 3c, with potential for reduction in hepatocyte stress and apoptosis as well as direct and indirect anti-fibrotic effects Historical improvements in biopsy-based measure
Slide 14: Phase 2a Trial: The BALANCED Study (Main Study)
PHASE 2A TRIAL: THE BALANCED STUDY (MAIN STUDY) Multiple endpoints, including liver fat reduction as well as paired biopsies, designed to provide proof of concept that Akero’s FGF21 approach combats major hallmarks of NASH 6 WEEKS 16 WEEKS 4-8 WEEKS NUMBER OF SUBJECTS 80 PRIMARY ENDPOINT Absolute ch
Slide 15: F4 Cohort Expansion (Cohort C)
F4 COHORT EXPANSION (COHORT C) The BALANCED study is being expanded to include a cohort of patients with compensated cirrhosis (F4), Child-Pugh Class A 6 WEEKS 16 WEEKS 4 WEEKS NUMBER OF SUBJECTS 30 PRIMARY ENDPOINT Safety and tolerability Selection of 50 mg dose based on PK-PD Modeling of Phase 1b
Slide 16: Extensive Development, Commercialization Experience
EXTENSIVE DEVELOPMENT, COMMERCIALIZATION EXPERIENCE INVOLVED IN 20+ MEDICINE APPROVALS • • • 19 years at Gilead Chief Medical Officer & HIV Division Head Major role in 11 NDA/MAA approvals • • • • • Over 30 years at Pfizer & Glaxo CSO of Pfizer’s cardiovascular and metabolic disease unit Head of Gro
Slide 17: Strong Financial Position
STRONG FINANCIAL POSITION completion 1H 2020 Projected initiation 17 - CONFIDENTIAL - CO M P L E TED UPSIZED IPO June 20, 2019 Q3 EA R N I N G S UPDATE September 30, 2019 SIGNIFICANT NEAR TERM MILESTONES ~$106M Raised in aggregate gross proceeds ~$148M Cash and cash equivalents Phase 2a Main Study p
Slide 18: Milestones
MILESTONES PROJECTED MILESTONES DELIVERED Liver Biopsy Read-out MRI-PDFF Read-out MAR 13 Last Patient 1st Dose Q2 1st Patient Dosed Q1 ~$106M Upsized IPO DEC 16 $45.5M Series B JUL 2 JUN 20 Amgen License $45M Series A DEC 5 JUN 8 18 - CONFIDENTIAL - 2020 2019 2018
Slide 19: Thank You.
THANK YOU. CORPORATE PRESENTATION
Akero Therapeutics — Investor Presentation (January 2020) on 6ix